Lymphatic Mapping After Previous Breast Surgery (LABS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rationale: Like in primary breast cancer, prognosis in recurrent breast cancer is correlated with regional lymph node status. Therefore, axillary staging may be warranted in patients with recurrent disease and intact axillary nodes, although this has not been described in guidelines yet. The lymphatic drainage pathways in the breast and/or axilla could have been changed due to prior surgery and/or radiotherapy. These aberrant drainage pathways could be detected with lymphatic mapping and sentinel node biopsy (SNB), leading to a more accurate staging.
Objective: To assess the technical feasibility of lymphoscintigraphy after prior breast surgery. A second goal is to investigate whether or not previous breast surgery (with or without radiotherapy) significantly changes the lymphatic drainage pathways of the breast.
| Condition | Intervention |
|---|---|
|
Breast Cancer Sentinel Node |
Radiation: Lymphoscintigraphy |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Lymphatic Mapping After Previous Breast Surgery |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Sentinel Node Biopsy
All women who has Sentinel Node Biopsy as their primary treatment of the axilla
|
Radiation: Lymphoscintigraphy
in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
Other Name: 99mTc-colloidal-albumin
|
|
Axillary Lymph Node Dissection
All women who had Axillary Lymph Node Dissection as primary axillary treatment
|
Radiation: Lymphoscintigraphy
in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
Other Name: 99mTc-colloidal-albumin
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Sampling Method: | Non-Probability Sample |
We included patients that received BCT with SNB and/or ALND for primary breast cancer located in the upper-outer quadrant of one breast at least 3 years before this analysis. Patients were excluded if they had breast surgery for other reasons than breast cancer, had recurrent breast cancer or had a former allergic reaction to 99mTc-colloidal-albumin.
44 patients were included and were divided into two groups according to previous surgical treatment of the axilla, being the sentinel node biopsy group and the Axillary Lymph Node Dissection group
Inclusion Criteria:
- treatment with BCT with SNB and/or ALND for primary breast cancer
- previous primary breast cancer located in the upper-outer quadrant of one breast
- Primary breast cancer treatment at least 3 years before the analysis, with or without adjuvant chemo- or hormonal therapy.
Exclusion Criteria:
- breast surgery for other reasons than breast cancer
- recurrent breast cancer
- former allergic reaction to 99mTc-colloidal albumin.
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01164748 History of Changes |
| Other Study ID Numbers: | NL22080.060.08 |
| Study First Received: | July 16, 2010 |
| Last Updated: | July 16, 2010 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on June 17, 2013